The Academy of Oncology Nurse & Patient Navigators (AONN+) is pleased to share that long-time member, and seasoned healthcare executive Rani Khetarpal, MBA, has been announced as President of its ...

Oral delivery of proteins and peptides has historically faced significant technical barriers due to the enzymatic degradation and poor permeability of macromolecules in the gastrointestinal (GI) tract ...

Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vor Biopharma (VOR – Research Report), Clearside Biomedical (CLSD – Research Report) and Arge ...

Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration ...

Rani Therapeutics announced positive preclinical data for RT-114 and semaglutide, advancing toward Phase 1 obesity trials in mid-2025. Rani Therapeutics Holdings, Inc. has announced preclinical ...

SAN JOSE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or“Rani”) (Nasdaq: RANI), a clinical-stage ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), a pharmaceutical company trading at $1.09 per share, disclosed on Monday that it has received a notice from the Nasdaq Stock Exchange regarding ...

Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), a pharmaceutical company trading at $1.09 per share, disclosed on Monday that it has received a notice from the Nasdaq Stock Exchange regarding non ...

March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics ...

Please go ahead. Thank you, Operator. Please turn to Slide 2. Joining us on the call today from Rani Therapeutics are Chief Executive Officer, Talat Imran; and Chief Financial Officer, Svai Sanford.